Pyoderma gangrenosum is an ulcerating disorder of the skin with sterile neutrophilic inflammation that may be seen in up to 5% of patients with chronic ulceration of the legs. 1 Typically painful, it ...

Ulcerative pyoderma gangrenosum is a rare inflammatory disease with an incidence of 3–10 cases per million per year. 1 Consideration of the diagnosis is based on its classic morphological features: ...

Following the recommendation, InflaRx intends to halt further development of vilobelimab for the PG indication. The company ...

Orphan Drug Designation granted for treatment of pyoderma gangrenosum (PG) from US FDA and EMAProductive end-of-phase II meeting with FDA held for PG; dialogue ongoing related to Phase III program ...

JENA, Germany, March 08, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement ...

JENA, Germany, May 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that ...

SPOKANE, Wash. – Ryan Becker, a Spokane resident, is battling an extremely rare skin condition known as pyoderma gangrenosum. After visits to the Mayo Clinic and Johns Hopkins, Becker has been ...

InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum Provided by GlobeNewswire May 27, 2025, 10:30:00 PM ...

Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, said: “We would like to thank the dedicated physicians and pyoderma gangrenosum patients for their participation in this ...